Mainz Biomed shares surge 33.75% premarket after $6M private placement with David Lazar funds U.S. pancreatic cancer pivot.

Mainz Biomed surged 33.75% in premarket trading following the announcement of a $6.0 million private placement with investor David Lazar, structured in two $3.0 million tranches, to strengthen liquidity and fund its transition to a U.S.-focused pancreatic cancer screening program. The financing, completed in part on February 13, 2026, also led to Lazar being appointed Chairman of the Board, signaling renewed leadership and strategic direction. The company plans to reduce costs by winding down its German subsidiary and selling colorectal cancer screening assets, aligning with its pivot to prioritize U.S. growth opportunities. These moves underscore improved operational flexibility and a clear path to long-term value creation, directly driving the sharp premarket rally.